Indolfi Ciro, Barillà Francesco, Basso Cristina, Ciccone Marco Matteo, Curcio Antonio, Mancone Massimo, Mercuro Giuseppe, Muscoli Saverio, Nodari Savina, Pedrinelli Roberto, Romeo Francesco, Sinagra Gianfranco, Filardi Pasquale Perrone
Società Italiana di Cardiologia, Roma - Istituto di Cardiologia, Università degli Studi "Magna Graecia", Catanzaro - Mediterranea Cardiocentro, Napoli.
Società Italiana di Cardiologia, Roma - Dipartimento di Medicina dei Sistemi, Università degli Studi "Tor Vergata", Roma.
G Ital Cardiol (Rome). 2021 May;22(5):363-375. doi: 10.1714/3592.35745.
In over a year, the COVID-19 pandemic caused 2.69 million deaths and 122 million infections. Social isolation and distancing measures have been the only prevention available for months. Scientific research has done a great deal of work, developing in a few months safe and effective vaccines against COVID-19. In the European Union, nowadays, four vaccines have been authorized for use: Pfizer-BioNTech, Moderna, ChAdOx1 (AstraZeneca/Oxford), Janssen (Johnson & Johnson), and three others are currently under rolling review.Vaccine allocation policy is crucial to optimize the advantage of treatment preferring people with the highest risk of contagion. These days the priority in the vaccination program is of particular importance since it has become clear that the number of vaccines is not sufficient for the entire Italian population in the short term. Cardiovascular diseases are frequently associated with severe COVID-19 infections, leading to the worst prognosis. The elderly population suffering from cardiovascular diseases is, therefore, to be considered a particularly vulnerable population. However, age cannot be considered the only discriminating factor because in the young-adult population suffering from severe forms of heart disease, the prognosis, if affected by COVID-19, is particularly ominous and these patients should have priority access to the vaccination program. The aim of this position paper is to establish a consensus on a priority in the vaccination of COVID-19 among subjects suffering from different cardiovascular diseases.
在一年多的时间里，新冠疫情导致269万人死亡，1.22亿人感染。数月来，社交隔离和保持社交距离措施一直是唯一可行的预防手段。科研工作付出巨大努力，在短短几个月内研发出了安全有效的新冠疫苗。在欧盟，目前已有四种疫苗获批使用：辉瑞 - 生物科技疫苗、莫德纳疫苗、ChAdOx1（阿斯利康/牛津）疫苗、杨森（强生）疫苗，另有三种疫苗正在进行滚动审查。疫苗分配政策对于优化治疗优势、优先照顾感染风险最高的人群至关重要。如今，疫苗接种计划中的优先级尤为重要，因为很明显短期内疫苗数量不足以满足全体意大利人口的需求。心血管疾病常与重症新冠感染相关，导致最糟糕的预后。因此，患有心血管疾病的老年人群体被视为特别脆弱的群体。然而，年龄不能被视为唯一的区分因素，因为在患有严重心脏病的年轻成年人群体中，如果感染新冠，预后会特别凶险，这些患者应优先获得疫苗接种。本立场文件的目的是就不同心血管疾病患者的新冠疫苗接种优先级达成共识。
